Απεικονιστική Εκτίμηση Ανταπόκρισης στην Ανοσοθεραπεία

Ιωάννης Χ. Γκιόζος
Πνευμονολόγος MD, PhD, FCCP

Ογκολογική Μονάδα
Γ’ Πανεπιστημιακή Παθολογική Κλινική
ΝΝΘΑ “Η Σωτηρία”
TUMOR RESPONSE CRITERIA

A set of published *mainly imaging rules* that define when cancer patients improve “respond”, stay the same “stable” or worsen “progression” during treatments, which is a “common language” between care givers.
<table>
<thead>
<tr>
<th>WHO (bidimensional response assess)</th>
<th>RECIST v1.1 (unidimensional response assess)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CR</strong> Disappearance of all target lesions without any residual lesion; confirmed at 4 weeks</td>
<td>Disappearance of all target lesions; confirmed at 4 weeks</td>
</tr>
<tr>
<td><strong>PR</strong> 50% or more decrease in target lesions, without a 25% increase in any one target lesion; confirmed at 4 weeks</td>
<td>≥30% reduction in the sum of the longest diameter of target lesions, taking as reference the baseline study; confirmed at 4 weeks</td>
</tr>
<tr>
<td><strong>SD</strong> Neither PR or PD criteria are met</td>
<td>Neither PR nor PD criteria are met, taking as reference the smallest sum of the longest diameter recorded since treatment started</td>
</tr>
<tr>
<td><strong>PD</strong> ≥25% increase in the size of measurable lesion or appearance of new lesions</td>
<td>≥20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or appearance of new lesions</td>
</tr>
</tbody>
</table>
Essentials for immunotherapy effects on Response Assessment
Immune-related Response Criteria

**RECKIST1.1 remains the gold standard for evaluating treatment response in solid tumors**

- However, new lesions or flare equals progressive disease under RECKIST1.1 guidelines
- Inaccurate interpretation of response can result in premature termination of therapy and patient removal from a trial

**Need new response criteria**

- Immune-related response criteria (irRC), 2009
  - Based on WHO criteria
- Immune-related RECKIST (irRECKIST), 2013
  - Combines elements of irRC and RECKIST
- Immune RECKIST (iRECKIST), 2017
  - Standardizes and validates immune response criteria
- All account for novel response patterns seen with immunotherapies
# irRC – irRECIST – iRECIST

<table>
<thead>
<tr>
<th>Measurement Modality</th>
<th>irRC: Bidimensional (Longest Diameter × Longest Perpendicular Diameter)</th>
<th>irRECIST: Unidimensional (Longest Diameter)</th>
<th>iRECIST: Unidimensional (Longest Diameter)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline lesion size, mm</td>
<td>5 × 5</td>
<td>≥ 10</td>
<td>≥ 10</td>
</tr>
<tr>
<td>Minimum no. of lesions to be measured for assessment</td>
<td>10 lesions in total; 5 per organ</td>
<td>5 lesions in total; 2 per organ</td>
<td>5 lesions in total; 2 per organ</td>
</tr>
<tr>
<td>Appearance of new lesions</td>
<td>Incorporated in the sum of the measurements</td>
<td>Incorporated in the sum of the measurements</td>
<td>IUPD; becomes iCPD if PD is eventually confirmed</td>
</tr>
<tr>
<td>CR</td>
<td>Disappearance of all lesions</td>
<td>Disappearance of all lesions</td>
<td>Disappearance of all lesions</td>
</tr>
<tr>
<td>PR</td>
<td>≥ 50% decrease from baseline</td>
<td>≥ 30% decrease from baseline</td>
<td>≥ 30% decrease from baseline</td>
</tr>
<tr>
<td>SD</td>
<td>Neither CR nor PD is met</td>
<td>Neither CR nor PD is met</td>
<td>Neither CR nor PD is met</td>
</tr>
<tr>
<td>PD</td>
<td>≥ 25% increase in the nadir of the sum of target lesions</td>
<td>≥ 20% increase in the nadir of the sum of target lesions with a minimum of 5 mm</td>
<td>≥ 20% increase in the nadir of the sum of target lesions with a minimum of 5 mm</td>
</tr>
<tr>
<td>Confirmation of PD</td>
<td>Yes</td>
<td>Yes, at least 4 weeks after, and up to 12 weeks</td>
<td>Yes, at least 4 weeks after, and up to 8 weeks</td>
</tr>
</tbody>
</table>

Abbreviations: iRC, immune-related response criteria; irRECIST, immune-related RECIST; iRECIST, immunotherapy RECIST; IUPD, immune unconfirmed progressive disease; iCPD, immune confirmed progressive disease; PD, progressive disease; CR, complete response; PR, partial response; SD, stable disease.

Brocoman E, 2018 ASCO Educational Book
iRECISt 2017
Seymour et al. Lancet Oncol 2017;18:e143-52

- Developed by the RECIST working group
- Standardizes and validates immune response criteria
- Addresses key questions about tumor assessment with immunotherapy

- Resetting the bar if RECIST Progressive Disease (PD) is followed at next time point (TP) by tumor shrinkage
- New overall response is defined as “iUPD” or immune unconfirmed progressive disease
Patterns of response to cancer immunotherapy can be heterogeneous.

**Initial Response**
- "Stable disease": Slow, steady decline in tumour volume
- Change from baseline SPD (%)

**PD then Response**
- Change from baseline SPD (%)

**New Lesions then Response**
- Change from baseline SPD (%)

**Thresholds for response or progressive disease**

*RECIST OR WHO CRITERIA MAY NOT BE APPROPRIATE TO ASSESS*

## Pseudoprogression

<table>
<thead>
<tr>
<th></th>
<th>Baseline assessment</th>
<th>First assessment</th>
<th>Later assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pseudoprogression</strong></td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Disease progression</strong></td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
</tbody>
</table>

- Pseudoprogression may be due to
  - tumor infiltration by immune cells *or*
  - continued tumor growth until a sufficient response develops (transient progression)
Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer

Sharyn I. Katz, MD, MTR, a,* Mark Hammer, MD, a,b Stephen J. Bagley, MD, c
Charu Aggarwal, MD, MPH, c Joshua M. Baum, MD, c Jeffrey C. Thompson, MD, c
Arun C. Nachiappan, MD, a Charles B. Simone II, MD, d Corey J. Langer, MD c

Figure 2. Radiologic pseudoprogression in a patient with NSCLC who was receiving nivolumab therapy. (A) Axial computed tomography images from a 68-year-old patient with adenocarcinoma of the lung after a lobectomy with known pulmonary metastasis (arrows) at baseline. (B) At 2 months of therapy there were new and enlarged pulmonary nodules. By 3 months of therapy, the pulmonary nodules had decreased in size and number (C) and at 6 months of therapy they had nearly resolved (D).

Most Clinically Suspected Cases of Radiologic Pseudoprogression in NSCLC Being Treated with Anti-PD-1 Agents Were True Cancer Progression
Last Evaluation of Response is iRECIST in Immunotherapies
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour, Jan Bogaerts, Andrea Perrone, Robert Ford, Lawrence H Schwartz, Sumithra Mandrekar, Nancy U Lin, Saskia Litière, Janet Dancey, Alice Chen, F Stephen Hodi, Patrick Therasse, Otto S Hockstra, Lalitha K Shankar, Jedd D Wolchok, Marcus Ballinger, Caroline Caramella, Elisabeth G E de Vries, on behalf of the RECIST working group

Figure 2: RECIST 1.1 and iRECIST: an example of assessment
Prefix “i” indicates immune responses assigned using iRECIST; others without “i” are confirmed by RECIST 1.1. RECIST=Response Evaluation Criteria in Solid Tumours. iCR=complete response. iCPD=complete progression. iPR=partial response. iSD=stable disease. iUPD=unconfirmed progression. TP=timepoint.

These guidelines are not intended to define or guide clinical practice or treatment decisions, but rather to provide a consistent framework for the management of data collected in clinical trials of immune-based therapies. Treatment decisions rest with the patient and their healthcare team.
RECIST (Response Evaluation Criteria in Solid Tumours) provides a simple and pragmatic methodology to evaluate the activity and efficacy of new cancer therapeutics in solid tumors, using validated and consistent criteria to assess changes in tumor burden. The RECIST Working Group comprises representatives of the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) of the United States and Canadian Cancer Trials Group (CCTG), as well as several pharmaceutical companies. Its mission is to ensure that RECIST undergoes

http://www.eortc.org/recist/contact-us/
• New Imaging Assessment Tool for Response Rate Evaluation of Immunotherapy, Based on Clinical Trials

• The Understanding of full potential of Immunotherapies depends on new tools such as iRECIST